Reading HURA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HURA free→Reading HURA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HURA free→QuarterlyIQ Insights · HURA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”). The Loan Agreement provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million. On May 26, 2026, the Company received…
Results of Operations and Financial Condition. On May 15, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the three months ended March 31, 2026, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Entry into a Material Definitive Agreement. On April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company upon the terms and conditions set forth in the Loan Agreement. The Company intends to use borrowings under the Loan Agreement for general corporate purposes, including the funding of the Comp…
The Company claims an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), for the private placement of the Loan Fee Shares and Conversion Shares, as the Loan Fee Shares and Conversion Shares will be issued solely to “accredited investors,” as such term is defined in the Securities Act of 1933, as amended (the “Securities Act”), and in reliance on the exemption from registration afforded by Section 4(a)(2) and/or Regulation D (Rule 506…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information provided in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 2, 2026, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) approved annual performance bonuses for 2025 for Dr. James Bianco, the Company’s President and Chief Executive Officer, and Dan Dearborn, the Company’s Chief Financial Officer, in the amount of $490,536…
Results of Operations and Financial Condition. On April 1, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the year ended December 31, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any pur…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 29, 2026, TuHURA Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 28, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price r…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 9, 2025, TuHURA Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (collectively, the “Purchasers”). The Purchase Agreement relates to the sale and issuance in a registered direct offering (such sale and issuance, the “Offering”), by the Company of an aggregate of: (i) 9,462,423 shares of the Company’s common stock, par value $0.00…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Entry into a Material Definitive Agreement. Amendment to Secured Promissory Note and Loan Agreement As disclosed in a Current Report on Form 8-K filed by TuHURA Biosciences, Inc. (the “Company”) on October 31, 2025, the Company previously entered into a Secured Promissory Note and Loan Agreement, dated October 27, 2025 (the “Loan Agreement”), with the Matthew Nachtrab Revocable Trust dated 12/18/2014 (the “Lender”). Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans…
Regulation FD Disclosure. On November 22, 2025, TuHURA Biosciences, Inc.’s (the “Company”) Registration Statement on Form S-3 (File No. 333-291239) (the “Shelf Registration Statement”) initially filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025, became effective in accordance with the provisions of Section 8(a) of the Securities Act of 1933, as amended (the “Securities Act”). As previously disclosed, on June 2, 2025, the Company completed its private placement…
Results of Operations and Financial Condition. On November 14, 2025, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the three months ended September 30, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed…
Entry into a Material Definitive Agreement. Bridge Loan Transaction On October 27, 2025, TuHURA Biosciences, Inc. (the “Company”) entered into a Secured Promissory Note and Loan Agreement (the “Loan Agreement”) with the Matthew Nachtrab Revocable Trust dated 12/18/2014 (the “Lender”). Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3,000,000 (the “Loans”) during a 30-day availability period beginning on the…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Entry into a Material Definitive Agreement. As previously announced, on June 2, 2025, TuHURA Biosciences, Inc. (the “Company”) and investors (the “Purchasers”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to issue to the Purchasers, in a private placement (the “Offering”), an aggregate of 4.76 million shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), together with warrant…
Results of Operations and Financial Condition. On August 14, 2025, TuHURA Biosciences, Inc. issued a press release reporting its financial results for the three months ended June 30, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any purpose, and shall not be…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 6, 2025, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) approved an increase to the annual base salaries of James A. Bianco, M.D., Chief Executive Officer, as well as Dan Dearborn, Chief Financial Officer, to $577,101 and $384,453, respectively, with such incr…
Entry into a Material Definitive Agreement. On June 2, 2025, TuHURA Biosciences, Inc. (the “Company”) and investors (the “Purchasers”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to issue to the Purchasers, in a private placement (the “Offering”), an aggregate of 4.76 million shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), together with warrants to purchase an equal nu…
Unregistered Sales of Equity Securities. The information set forth under
Results of Operations and Financial Condition. On May 15, 2025, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the three months ended March 31, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 12, 2025, TuHURA Biosciences, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Form 8-K”) to announce, among other things, the appointment of Dr. Craig Tendler to the Company’s Board of Directors (the “Board”) effective as of March 10, 2025. At the time the Initial Form 8-K was filed, the Board had not yet determined o…
Results of Operations and Financial Condition. On April 1, 2025, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the year ended December 31, 2024, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any pur…
Regulation FD Disclosure. On March 18, 2025, representatives of TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) began making presentations to investors, analysts, and others using the investor presentation attached to this Current Report on Form 8-K as Exhibit 99.1 (the “Investor Presentation”). The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others from time to time. B…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 7, 2025, the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) increased the size of the Board from five members to six members and appointed Dr. Craig Tendler to the Board, effective as of March 10, 2025, to serve as a director until the Company’s 2025 Annual Meeting of Stockholders and until his successor has b…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.